J Remon, E Auclin, L Zubiri, S Schneider, D Rodriguez-Abreu, N Minatta, O Gautschi, F Aboubakar, E Muñoz-Couselo, T Pierret, S I Rothschild, F Cortiula, K L Reynolds, C Thibault, A Gavralidis, N Blais, F Barlesi, D Planchard, B M D Besse
BACKGROUND: Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate ICB outcomes in this population, with a special focus on lung cancer. METHODS: We conducted a multicenter retrospective cohort study collecting real data of ICB use in patients with SOT and solid tumors. Clinical data and treatment outcomes were assessed by using retrospective medical chart reviews in every participating center...
April 22, 2024: ESMO Open